Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023 Feb 06, 2023 8:00am EST
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 03, 2023 4:01pm EST
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Jan 13, 2023 4:01pm EST
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference Jan 04, 2023 4:01pm EST
Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty Dec 20, 2022 4:33pm EST
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD Dec 19, 2022 7:00am EST
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Dec 15, 2022 4:01pm EST
Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting Dec 12, 2022 10:00am EST
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Dec 02, 2022 4:01pm EST
